- Poster presentation
- Open Access
Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
© Southwood et al; licensee BioMed Central Ltd. 2008
- Published: 15 September 2008
- Juvenile Idiopathic Arthritis
- Anterior Uveitis
- Juvenile Idiopathic Arthritis Patient
The British Society for Paediatric and Adolescent Rheumatology (BSPAR) Biologics Register monitors JIA patients treated with etanercept +/- methotrexate. We report duration of etanercept use and reasons for discontinuation, defined as cessation due to disease control or treatment failure; not including precautionary or temporary drug discontinuation for transient adverse events. Kaplan-Meier survival analysis was conducted with remaining patients censored at five years follow-up.
Reasons for stopping Etanercept
Discontinuations were due to treatment inefficacy rather than treatment intolerance in the steroid+ group (p = 0.01). Of the 5 discontinuations due to infection related adverse events, 4 were in the steroid+ group. Using 5 year Kaplan-Meier analysis, 55% of all etanercept treated patients (95% confidence intervals 44.4% – 65.6%) had not experienced treatment failure. Discontinuation at 5 years was not associated with initial disease severity by physicians global assessment, systemic arthritis subtype, starting etanercept before age 10, disease onset before age 5, concurrent methotrexate use or chronic anterior uveitis.
This article is published under license to BioMed Central Ltd.